Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer

NCT02120469 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02120469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02120469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2014
Completion date
March 3, 2020
Enrollment
27 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, her2/neu negative, progesterone receptor-negative, stage iv breast cancer, triple-negative breast carcinoma